SHL Telemedicine is an Israel-based company that provides remote cardiac monitoring and telehealth services to patients in Israel, Germany, and the U.S. The core service allows patients to transmit health data from home to SHL's telemedicine centers, where medical staff monitor their condition and intervene when needed. SHL's proprietary SmartHeart® platform is a 12-lead ECG device that patients can operate at home without clinical assistance — the foundation of SHL's consumer cardiac monitoring business. In Israel, SHL sells cardiac monitoring directly to consumers via monthly subscriptions, bundled with the SmartHeart® device. In Germany, SHL operates a B2B model, contracting with statutory health insurance funds to remotely monitor chronically ill patients, earning a per-patient fee. The U.S. business is early-stage, selling SmartHeart® devices to consumers and healthcare providers, with a direct-to-consumer subscription program launched in late 2023. SHL is also pursuing FDA over-the-counter clearance for SmartHeart®, which would broaden its U.S. addressable market. SHL's secondary business in Israel is Mediton, a B2B healthcare services provider offering occupational health exams, preventative check-ups, and insurance medical examinations to corporations, insurers, and government bodies under multi-year contracts. SHL's cost base is largely fixed given its 24/7 staffed telemedicine centers, making profitability sensitive to subscriber and patient volumes.